Clinical trials: ANLL
Leukemia
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00528398
- Testing
- cytarabine, idarubicin
- Where
- 2 sites in United States
- Volunteers
- 111 people
- Sponsor
- City of Hope Medical Center
Leukemia, Myeloid, Acute
Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
This phase I/2 trial studies the side effects and best dose of activated natural killer cells in treating patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.
- Trial name
- NCT01898793
- Testing
- Fludarabine, Cyclophosphamide, Leukapheresis
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- Washington University School of Medicine
Relapsed Pediatric ALL, Relapsed Pediatric AML
Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia
In this pilot study, eligible pediatric patients will be treated with 5 consecutive days of low dose daunorubicin. All patients who receive low dose daunorubicin will be evaluated daily for potential toxicity during those 5 days.
- Conditions
- Relapsed Pediatric ALL, Relapsed Pediatric AML, Refractory Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT04562792
- Testing
- Daunorubicin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Mercy Hospital Kansas City
Leukemia
Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00276601
- Testing
- arsenic trioxide, cytarabine, daunorubicin hydrochloride
- Where
- 7 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Bone Marrow Ablation, Leukemia
High-Dose Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Acute Leukemia in Remission
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Trial name
- NCT00002567
- Testing
- filgrastim, etoposide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
This phase I/II studies the side effects and best dose of natural killer cells before and after donor stem cell transplant and to see how well they work in treating patients with acute myeloid leukemia, myelodysplastic syndrome…
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Gene Mutations, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT01904136
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Bone Marrow Transplantation, Cyclophosphamide
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Acute Myeloid Leukemia
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
The purpose of this study is to compare the efficacy and safety of venetoclax combined with CACAG regimen with BAT regimen in the treatment of relapsed/refractory acute myeloid leukemia.
- Trial name
- NCT06084819
- Testing
- Azacytidine;Cytarabine;Aclacinomycin;Chidamide;Venetoclax;Granulocyte colony-stimulating factor, Best-Available Therapy(BAT) Regimen
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
Patients With Acute Myeloid Leukemia, Patients Receiving Induction/Consolidation Chemotherapy
Genetic Predictive Model Based on Single Nucleotide Polymorphisms in the DNA Repair Pathway and Drug Metabolis/Transport Pharmacogenetics in the Prediction of Response and Treatment Outcomes in Acute Myeloid Leukemia
The main component in the treatment of acute myeloid leukemia (AML) is consist of anthracycline (such as daunorubicin or idarubicin) and cytarabine.
- Trial name
- NCT01106144
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL)
Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM
A Study Evaluating the Safety and Efficacy of Transplantation of a single cord blood unit (CBU) of NiCord®, umbilical cord blood-derived Ex Vivo Expanded Stem and Progenitor Cells in Patients with Hematological Malignancies.
- Conditions
- Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)
- Trial name
- NCT01816230
- Testing
- NiCord®
- Where
- 15 sites in United States, Italy and 3 more
- Volunteers
- 36 people
- Sponsor
- Gamida Cell ltd
Pediatric Acute Myeloid Leukemia
Home Away From Home - Quality of Life Surveys
Treatment for pediatric acute myeloid leukemia (AML) involves intensive chemotherapy regimens that result in periods of profound neutropenia leaving patients susceptible to severe infectious complications.
- Trial name
- Aim 3 (NCT02777021)
- Where
- 15 sites in United States
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- Children's Hospital of Philadelphia
Cancer, Solid Tumor Cancer
Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer
This study entails enrolling participants that have been diagnosed with cancer to Olivia, a commercially available AI-enabled personal health platform developed by Tempus.
- Conditions
- Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia, Hematologic Malignancies
- Trial name
- ONCO-OLIVIA (NCT07756034)
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Tempus AI
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
HEM-SURVIVE: Structuralized Follow-up for Childhood Hematological Malignancy Survivors
This study aims to construct a structuralized follow-up model for survivors of childhood hematological malignancies in China. Using a multicenter prospective cohort design, it will identify the burden and risk factors of late…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Lymphoma, Leukemia
- Trial name
- NCT07483749
- Where
- 3 sites in China
- Volunteers
- 400 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Chronic Myeloproliferative Disorders, Leukemia
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00005804
- Testing
- cyclophosphamide, allogeneic bone marrow transplantation, radiation therapy
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Acute Myeloid Leukemia, Stem Cell Transplantation
GRanulocyte Augmented Cord Blood Transplantation for Poor Risk leukaEmia
Allogeneic stem cell transplantation is the only potentially curative therapy for patients with high-risk Acute Myeloid Leukaemia, but relapse is common and remains the leading cause of death.
- Conditions
- Acute Myeloid Leukemia, Stem Cell Transplantation, Stem Cell Transplantation, Hematopoietic, Cord Blood Stem Cell Transplantation
- Trial name
- GRACE (NCT07372885)
- Testing
- Cord blood transplantation + conditioning + granulocytes of variable days according to study design
- Where
- 3 sites in United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Manchester
Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
This is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of venetoclax-enhanced BUCY (Ven-BUCY) conditioning compared to the standard BUCY regimen in patients with high-risk…
- Conditions
- Acute Myeloid Leukemia, High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndromes, High-Risk Myelodysplastic Syndromes
- Trial name
- Ven-BUCY (NCT07183878)
- Testing
- Venetoclax, Busulfan (BU)
- Where
- China
- Volunteers
- 138 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia
Methotrexate or Pentostatin for Graft-versus-host Disease Prophylaxis in Risk-adapted Allogeneic Bone Marrow Transplantation for Hematologic Malignancies
The purpose of the study is to determine if participants who receive the GVHD prophylaxis medication pentostatin will have less severe hepatic toxicities than those receiving MTX.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Hodgkin's Disease
- Trial name
- NCT01188798
- Testing
- Methotrexate, Pentostatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- St. Jude Children's Research Hospital
Leukemia, Acute Myeloid Leukemia
BG1805 Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Children
This is a single-arm, single-dose dose-escalation and dose-expansion study.
- Trial name
- NCT06347458
- Testing
- BG1805
- Volunteers
- 24 people
- Sponsor
- Guangzhou Bio-gene Technology Co., Ltd
Acute Myeloid Leukemia
NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
A Study of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia.
- Trial name
- NCT04658004
- Testing
- NKG2D CAR T-cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhejiang University
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
This is a phase 1 dose escalation study to determine the safety of anti-FLT3 CAR-T in subjects with R/R AML. The primary objective is to assess safety.
- Trial name
- NCT06786533
- Testing
- Anti-FLT3 CAR-T cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Hemogenyx Pharmaceuticals LLC
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603)
Bone marrow transplants are one treatment option for people with leukemia or lymphoma. Family members or unrelated donors with a similar type of bone marrow usually donate their bone marrow to the transplant patients.
- Conditions
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell
- Trial name
- NCT00849147
- Testing
- Haploidentical Bone Marrow Transplantation, GVHD prophylaxis
- Where
- 17 sites in United States
- Volunteers
- 55 people
- Sponsor
- Medical College of Wisconsin
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.